Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 2 · 50%High 1 · 25%

Progression‐free survival · patients with EOC

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
no estimate extracted
1 study · 274 participants
High

Progression‐free survival · patients with ovarian cancer

Topotecon+Carboplatin+Paclitaxel may leads to higher progress free survival compared with carboplatin+Paclitaxel (low certainty).

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
HR 1.03 [1.03, 1.03]
2 studies · 1998 participants
Low

Progression free survival (platium‐sensitive) · patients with EOC

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
no estimate extracted
1 study · 220 participants
Moderate

Progression free survival (platium‐resistant) · patients with EOC

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
no estimate extracted
1 study · 220 participants
Moderate